Table 3.
Therapeutic efficacy by studying SNP and DMT2 patients’ genotype.
| Gene | SNP | Genotype | Control (n = 48) HbA1c < 7 (%) |
Non-Control (n = 55) HbA1c > 7 (%) |
* p = |
|---|---|---|---|---|---|
|
SLC22A1 (OCT1) |
rs72552763 | GAT/GAT | 23 (47.9%) | 21 (38.2%) | 0.392 |
| del/GAT | 18 (37.5%) | 28 (50.9%) | |||
| del/del | 7 (14.6%) | 6 (10.9%) | |||
| rs622342 | A/A | 22 (45.8%) | 19 (34.5%) | 0.324 | |
| A/C | 15 (31.3%) | 25 (45.5%) | |||
| C/C | 11 (22.9%) | 11 (20%) | |||
|
SLC22A2 (OCT2) |
rs316019 | C/C | 43 (89.6%) | 51 (92.7%) | 0.425 |
| A/C | 5 (10.4%) | 3 (5.5%) | |||
| A/A | 0 (0%) | 1 (1.8%) | |||
|
SLC22A3 (OCT3) |
rs2076828 | C/C | 40 (83.3%) | 38 (69.1%) | 0.232 |
| C/G | 7 (14.6%) | 14 (25.5%) | |||
| G/G | 1 (2.1%) | 3 (5.5%) | |||
| ABCB1 | rs1128503 | C/C | 13 (27.1%) | 14 (25.5%) | 0.710 |
| C/T | 19 (39.6%) | 26 (47.3%) | |||
| T/T | 16 (33.3%) | 15 (27.3%) | |||
| rs2032582 | G/G | 17 (35.4%) | 17 (31.5%) | 0.662 | |
| G/T | 21 (43.8%) | 22 (40.7%) | |||
| T/T | 8 (16.7%) | 9 (16.7%) | |||
| T/A | 0 (0%) | 2 (3.7%) | |||
| G/A | 2 (4.2%) | 4 (7.4%) | |||
| rs1045642 | C/C | 15 (31.3%) | 21 (38.2%) | 0.520 | |
| C/T | 21 (43.8%) | 25 (45.5%) | |||
| T/T | 12 (25%) | 9 (16.4%) | |||
| CYP2C9 | rs1799853 rs1057910 |
*1/*1 | 39 (81.3%) | 46 (83.6%) | 0.261 |
| *1/*2 | 7 (14.6%) | 3 (5.5%) | |||
| *1/*3 | 2 (4.2%) | 5 (9.1%) | |||
| *2/*3 | 0 | 1 (1.8%) | |||
| rs1934969 | A/A | 30 (62.5%) | 39 (70.9%) | 0.643 | |
| A/T | 14 (29.2%) | 13 (23.6%) | |||
| T/T | 4 (8.3%) | 3 (5.5%) |
* p for Chi square test.